Esomeprazole tablets launched by Cadila Pharma in India

Cadila Pharmaceuticals (Ahemdabad) has announced the launching of esomeprazole tablets for the treatment of hyperacidity and drug-induced gastritis under the brand name Esiloc.
As per the statement of the company, “Esiloc will be 50 per cent more economical, thus making it a superior yet affordable choice. It will be made available in 20 mg and 40 mg tablets,”

A proton pump inhibitor, Esomeprazole, works on the luminal surface of gastric parietal cells which results in inhibition of acid secretion. Esomeprazole and provides higher rates of healing of erosive gastro-oesophageal reflux (GERD) and sustained resolution of heartburn in patients.

  • Related Posts

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    New Delhi: Alembic Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP in…

    STF busts fake meds racket spread across 6 states

    Dehradun: Uttarakhand special task force (STF) on Friday busted an online fake medicine racket operating through a Facebook page that allegedly sold counterfeit drugs, including cancer medicines, at discounts of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    STF busts fake meds racket spread across 6 states

    STF busts fake meds racket spread across 6 states

    All the Way from Teeth to Tee: Hole in One

    All the Way from Teeth to Tee: Hole in One

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Chemists strike on May 20: Reasons behind today’s all-India strike

    Chemists strike on May 20: Reasons behind today’s all-India strike

    AbbVie loses patent plea for Hep C drug

    AbbVie loses patent plea for Hep C drug